Pharmaceutical News

RSS

Mott poll measures public's views about use of medical marijuana for children

Medical marijuana and children don't mix, most Americans say. While nearly two-thirds of people agree that their state should allow medical marijuana for adults, half as many - just over a third - say it should be allowed for children, according to today's University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health that included a national sample of adults in the U.S.

21 Apr 2015

New UM SOM study reveals why thiazide drugs not effective in some patients

Every year, more than 120 million prescriptions are written worldwide for thiazide drugs, a group of salt-lowering medicines used to treat high blood pressure. These drugs are often work very well, and over decades have saved hundreds of thousands of lives.

21 Apr 2015

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis.

20 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Lupin introduces first Brand product Zaxine in Canada

Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc.

20 Apr 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

20 Apr 2015

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

20 Apr 2015

Malaria parasites with Ap2mu gene mutation less sensitive to antimalarial drug artemisinin

Early indicators of the malaria parasite in Africa developing resistance to the most effective drug available have been confirmed, according to new research published in Antimicrobial Agents and Chemotherapy.

20 Apr 2015

Study shows epilepsy drug can protect vision of MS patients

A drug commonly taken to prevent seizures in epilepsy may surprisingly protect the eyesight of people with multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.

17 Apr 2015

Researchers explore benefits and risks of biosimilar antibodies

In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.

17 Apr 2015

Aspirin use continues to surge among older adults in US

A national survey suggests that slightly more than half of the older adults in the United States are now taking a daily dose of aspirin, even though its use is not recommended by the Food and Drug Administration for most people who have not yet had a heart attack or stroke.

17 Apr 2015

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.

From Baxter International Inc. 16 Apr 2015

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar High Tech Center, the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Company, have announced collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry.

16 Apr 2015

Study looks at dabigatran adherence across Veterans Health Administration sites

Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication, according to a study in the April 14 issue of JAMA.

16 Apr 2015

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune announced today that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system...

16 Apr 2015

Itraconazole drug shows potential in cancer treatment

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.

16 Apr 2015

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

AbbVie today announced that the Japanese Ministry of Health, Labour and Welfare has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir.

16 Apr 2015

New herbal tea to treat malaria in Africa

Malaria is a critical health problem in West Africa, where traditional medicine is commonly used alongside modern healthcare practices. An herbal remedy derived from the roots of a weed, which was traditionally used to alleviate malarial symptoms, was combined with leaves and aerial portions from two other plants with antimalarial activity, formulated as a tea, and eventually licensed and sold as an antimalarial phytomedicine.

15 Apr 2015

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products.

15 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

Pharmaceutical News

Mott poll measures public's views about use of medical marijuana for children

New UM SOM study reveals why thiazide drugs not effective in some patients

Two existing drugs may potentially become new drug target for multiple sclerosis

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Lupin introduces first Brand product Zaxine in Canada

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Malaria parasites with Ap2mu gene mutation less sensitive to antimalarial drug artemisinin

Study shows epilepsy drug can protect vision of MS patients

Researchers explore benefits and risks of biosimilar antibodies

Aspirin use continues to surge among older adults in US

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

Study looks at dabigatran adherence across Veterans Health Administration sites

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Itraconazole drug shows potential in cancer treatment

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

New herbal tea to treat malaria in Africa

Pivotal enters into sales, distribution agreement for BeneFishial family of products

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News